Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Cephalexin

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Chewable Tablets Multiple FDA labelers Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Jun 22, 2026, 10:41 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Jun 22, 2026, 10:41 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Jun 13, 2026, 11:29 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Image coming soon
Cephalexin

Cephalexin

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Chewable Tablets Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Cephalexin

Cephalosporin antibiotic used for susceptible bacterial infections (often skin/soft tissue). Species commonly shown: Both, Dog.

Generic name
Cephalexin
Brand names
Rilexine®, Cephalexin monohydrate, RILEXINE
Manufacturer
Multiple FDA labelers
Species
Both, Dog
Dosage forms
Chewable Tablets
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Rilexine® Cephalexin monohydrate RILEXINE
Dosage forms
Chewable Tablets

Indications / Uses

Cephalosporin antibiotic used for susceptible bacterial infections (often skin/soft tissue).

Administration / How To Give

Oral

Storage

Store at room temperature.

Warnings / Contraindications

Avoid in pets with known cephalosporin allergy.

  • Avoid in pets with known cephalosporin allergy.

Side Effects

GI upset, decreased appetite.

FAQ

Both, Dog

Yes. Roxee shows this as prescription-only.

Chewable Tablets

Store at room temperature.

Related Medications

Amoxicillin-Clavulanate Same category: Antibiotics Cefovecin Same category: Antibiotics Enrofloxacin Same category: Antibiotics Ivermectin, Pyrantel Same category: Antibiotics Melarsomine Dihydrochloride Same category: Antibiotics Metronidazole Same category: Antibiotics

Related Conditions

Bacterial pyoderma Pyoderma (superficial/deep)

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Avoid in pets with known cephalosporin allergy
  • Loss of appetite (1 reports)
  • Fever (1 reports)
  • Drinking a lot (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Cephalexin; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-055018
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 10 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-055018
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-055018
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Loss of appetite (1 reports), Fever (1 reports), Drinking a lot (1 reports), Diarrhea (1 reports), Decreased appetite (1 reports)

Body systems represented Signal grouping

Digestive (4), Skin & allergy (2), Behavior (1), Other (25)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (17 reports), Cat (15 reports)

Breed metadata in reports Metadata only

['Shepherd (unspecified)', 'Dog (unknown)'] (2), ['Pointer (unspecified)', 'Dog (unknown)'] (1), Terrier - Bull - American Pit (1), Terrier - Bull (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Cephalexin fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Avoid in pets with known cephalosporin allergy, Loss of appetite, Fever, Drinking a lot

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Cephalexin brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-055018 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. Medication usage source · fda_animal_drugs · quick facts
  5. FOI · document · documents
  6. SPL · document · documents
  7. Structured Product Label · document · documents
  8. Structured Product Label · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 7:40 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Avoid in pets with known cephalosporin allergy
  • Loss of appetite
  • Fever
  • Drinking a lot

Most reported reactions:

  • Loss of appetite (1 reports)
  • Fever (1 reports)
  • Drinking a lot (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Dog
Indication / use
For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.
Form / route / dose
Form: Chewable Tablets
Route: Oral
Confirm product label and patient-specific plan.
Warnings
  • High: Avoid in pets with known cephalosporin allergy.
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Chewable Tablets
Identifiers:
NADA: 141326 NDC Package: 51311-026-10 NDC Package: 51311-036-10 NDC Package: 51311-046-10 NDC Package: 73309-179-01 NDC Package: 73377-243-01 NDC Package: 73377-243-02 NDC Product: 51311 NDC Product: 73309 NDC Product: 73377
Source metadata:

Warnings / Contraindications

Avoid in pets with known cephalosporin allergy.

  • High: Avoid in pets with known cephalosporin allergy.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
8
Matching reports
1
Active filters
2
Selected filters
Reaction: Other abnormal test result NOS Clear Body system: Digestive Clear
Reset
Drill into common report signals
Lethargy (see also Central nervous system depression in Neurological) (4) Death (3) Other abnormal test result NOS (3) Conjunctivitis (2) Other (7) Digestive (4) Effectiveness (4) Neurologic (4)
Showing up to 50 matching reports.

USA-USFDACVM-2025-US-072729

Received 2025-12-05 · MSK · MSK

Non-serious
Species
Dog
Breed
Terrier - Bull
Size / weight
25-49 lb (17.6 Kilogram)
Age
4-7 years (7 Year)
Sex
Female Neutered
Region
USA
Reactions
Leucopenia NOSAnaemia NOSHypoalbuminaemiaNeutropeniaPyodermaReduced globulinsHypophosphataemiaNon-regenerative anaemiaLow serum alkaline phosphatase (ALP)Pale mucous membraneElevated alanine aminotransferase (ALT)Decreased packed cell volume (PCV)Lethargy (see also Central nervous system depression in Neurological)HypocalcaemiaElevated aspartate aminotransferase (AST)HypoproteinaemiaProteinuriaElectrolyte disorderDisorder of red blood cell NOSElevated creatine-kinase (CK)Other coagulation investigation abnormalityIncreased band neutrophiliaElevated mean corpuscular volume (MCV)LymphopeniaOther abnormal test result NOSDiarrhoeaPanleucopeniaEosinopeniaDecreased haematocritIncreased percentage reticulocytes
Body systems
OtherNeurologicDigestive
Outcomes
Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
10
Species represented
2
Grouped by Body System
Digestive (4) · Loss of appetite, Diarrhea, Decreased appetite Skin & allergy (2) · Hair loss at application site, Facial swelling (possible allergy) Behavior (1) · Behavioral disorder (unspecified) Other (25) · Fever, Falling, Epidermal collarette
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Digestive 1 Cat 1
Digestive 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1

Species coverage: Dog (17) Cat (15)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Skin & allergy Cat Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Digestive Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Behavior Cat Non-serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Source metadata:

Storage & Handling

Store at room temperature.

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Rilexine® SPL · SPL Cephalexin Monohydrate SPL SPL · Structured Product Label RILEXINE SPL SPL · Structured Product Label

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

5

FOI

1

Rilexine®

SPL · SPL

Open original
FDA Structured Product Label

Rilexine®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Virbac AH, Inc.
NADA
141-326
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
Four tablet sizes containing 75 mg, 150 mg, 300 mg, or 600 mg of cephalexin.

Dogs

Indication
For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.
Dosage
The recommended dose is 22 mg/kg (10 mg/lb) of body weight twice daily for 28 days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Oral Use in Dogs Only.

Cephalexin Monohydrate SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Cephalexin Monohydrate. Use the source link for the full official labeling record.

RILEXINE SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for RILEXINE. Use the source link for the full official labeling record.

Cephalexin monohydrate SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Cephalexin monohydrate. Use the source link for the full official labeling record.

Cephalexin Monohydrate SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Cephalexin Monohydrate. Use the source link for the full official labeling record.

UCM318614.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Cephalexin Monohydrate Cephalexin monohydrate RILEXINE
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Chewable Tablets • Oral
Applications: NADA 141-326
NDC: Packages 51311-026-10 51311-036-10 51311-046-10 73309-179-01 73377-243-01 73377-243-02 • Products 51311 73309 73377
Documents: 1 (FOI: 1) • SPL: 1 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 47 • Cat 7 • View
Case summaries: 8 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Avoid in pets with known cephalosporin allergy. (Contraindication, High)
Top reaction signals
Loss of appetite (1) Fever (1) Drinking a lot (1) Diarrhea (1) Decreased appetite (1) Death by euthanasia (1) Death (1) Deafness (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141326 NDC Package: 51311-026-10 NDC Package: 51311-036-10 NDC Package: 51311-046-10 NDC Package: 73309-179-01 NDC Package: 73377-243-01 NDC Package: 73377-243-02 NDC Product: 51311 NDC Product: 73309 NDC Product: 73377
Package NDC Product NDC Form / Route Status
51311-026-10 51311 -
51311-036-10 51311 -
51311-046-10 51311 -
73309-179-01 73309 -
73377-243-01 73377 -
73377-243-02 73377 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Cephalexin Monohydrate SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • RILEXINE SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Cephalexin monohydrate SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Cephalexin Monohydrate SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • UCM318614.pdf • FOI summary • Official • Feb. 22, 2024
    FDA FOI summary for application 141326

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 121 Clinical 4 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: GI upset, decreased appetite. (Clinical, 2026-04-11)
  • storage_handling: Store at room temperature. (Clinical, 2026-04-12)
  • storage_handling: Store at room temperature. (Clinical, 2026-04-11)
  • storage_handling: Store at room temperature. (Clinical, 2026-02-12)
  • contraindications: Avoid in pets with known cephalosporin allergy. (Official, 2026-04-12)
  • contraindications: Avoid in pets with known cephalosporin allergy. (Official, 2026-04-11)
  • contraindications: Avoid in pets with known cephalosporin allergy. (Official, 2026-02-12)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-22)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-22)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-21)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-20)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-13)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-12)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-12)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-11)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-11)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-10)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-09)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-08)
  • indications: For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius. (Official, 2026-06-07)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Rilexine®
RX
Cephalexin
Chewable Tablets • Oral
Label highlights
Official documents
Virbac AH, Inc. NADA 141-326 Approved Feb 22, 2024

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog
Composition / specifications
Four tablet sizes containing 75 mg, 150 mg, 300 mg, or 600 mg of cephalexin.
Dogs
Indication
For the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.
Dosage
The recommended dose is 22 mg/kg (10 mg/lb) of body weight twice daily for 28 days.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For Oral Use in Dogs Only.

FDA page: Open in Animal Drugs @ FDA

Usage

Cephalosporin antibiotic used for susceptible bacterial infections (often skin/soft tissue).

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Avoid in pets with known cephalosporin allergy.

Side Effects

GI upset, decreased appetite.

Source: FDA openFDA • Reference

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Dog Diarrhea (1) • Cat Decreased appetite (1) • Cat Blood in vomit (1) • Dog

Showing top 5 for Digestive.

Skin & allergy
Hair loss at application site (1) • Cat Facial swelling (possible allergy) (1) • Cat

Showing top 5 for Skin & allergy.

Behavior
Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other
Fever (1) • Cat Falling (1) • Cat Epidermal collarette (1) • Dog Eosinopenia (1) • Dog Elevated mean corpuscular volume (1) • Dog
Show more (20)
Elevated creatine-kinase (1) • Dog Elevated aspartate aminotransferase (1) • Dog Elevated alanine aminotransferase (1) • Dog Electrolyte disorder (1) • Dog Dry mouth (1) • Cat Drowsiness - systemic disorder (1) • Cat Drinking a lot (1) • Dog Disorder of red blood cell NOS (1) • Dog Dilated pupils (1) • Cat Digestive tract stasis (1) • Cat Decreased packed cell volume (1) • Dog Decreased haematocrit (1) • Dog Death by euthanasia (1) • Cat Death (1) • Cat Deafness (1) • Dog Dazed (1) • Cat Constipation (1) • Cat Conjunctivitis (1) • Dog Anaemia NOS (1) • Dog Abnormal movement NOS (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, ['Pointer (unspecified)', 'Dog (unknown)'], Male, 15 year, 35.698 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Lack of efficacy - NOS, Death, Local erythema, Underdose, Tiredness (lethargy)… • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-075270
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 35.698 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Lack of efficacy - NOS Death Local erythema Underdose Tiredness (lethargy) Blood in vomit
Outcomes: Died

Dog, Terrier - Bull - American Pit, Male, 13 year, 28.894 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Pain NOS, Urinary incontinence, Tiredness (lethargy), Loss of appetite, Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-072922
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 13.00 Year
  • Weight: 28.894 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Pain NOS Urinary incontinence Tiredness (lethargy) Loss of appetite Death
Outcomes: Died

Dog, Terrier - Bull, Female, 7 year, 17.6 kilogram • Drug: MSK, Unknown • Reactions: Leucopenia NOS, Anaemia NOS, Hypoalbuminaemia, Neutropenia, Pyoderma… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-072729
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 7.00 Year
  • Weight: 17.600 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Leucopenia NOS Anaemia NOS Hypoalbuminaemia Neutropenia Pyoderma Reduced globulins Hypophosphataemia Non-regenerative anaemia Low serum alkaline phosphatase Pale mucous membrane Elevated alanine aminotransferase Decreased packed cell volume Tiredness (lethargy) Hypocalcaemia Elevated aspartate aminotransferase Hypoproteinaemia Proteinuria Electrolyte disorder Disorder of red blood cell NOS Elevated creatine-kinase Other coagulation investigation abnormality Increased band neutrophilia Elevated mean corpuscular volume Lymphopenia Other abnormal test result NOS Diarrhea Panleucopenia Eosinopenia Decreased haematocrit Increased percentage reticulocytes
Outcomes: Ongoing

Dog, ['Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog)', 'Dog (unknown)'], Unknown, 11 year, 18.597 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Lack of efficacy - NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-071459
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Unknown
  • Age: 11.00 Year
  • Weight: 18.597 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Lack of efficacy - NOS
Outcomes: Ongoing

Dog, Retriever - Golden, Female, 5 year, 30.935 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Vasculitis, Pinnae disorder, Head shake - ear disorder, Underdose • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-071676
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 5.00 Year
  • Weight: 30.935 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Vasculitis Pinnae disorder Head shake - ear disorder Underdose
Outcomes: Ongoing

Dog, ['Shepherd (unspecified)', 'Dog (unknown)'], Female, 11 month • Drug: MSK, Unknown • Reactions: Fracture, Thrombocytopenia, Respiratory tract infection NOS, Conjunctivitis, Unclassifiable adverse event… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-073723
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.00 Month
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Fracture Thrombocytopenia Respiratory tract infection NOS Conjunctivitis Unclassifiable adverse event Other abnormal test result NOS Lack of efficacy (endoparasite) - tapeworm
Outcomes: Outcome Unknown

Dog, ['Shepherd (unspecified)', 'Dog (unknown)'], Female, 11 month • Drug: MSK, Unknown • Reactions: Fracture, Thrombocytopenia, Respiratory tract infection NOS, Conjunctivitis, Unclassifiable adverse event… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-068774
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.00 Month
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Fracture Thrombocytopenia Respiratory tract infection NOS Conjunctivitis Unclassifiable adverse event Other abnormal test result NOS Lack of efficacy (endoparasite) - tapeworm
Outcomes: Outcome Unknown

Cat, Cat (unknown), Mixed • Drug: MSK, Intravenous, Dose: 22 Milligram per kilogram • Reactions: Death, Haematochezia, Decreased appetite, Regurgitation, Tiredness (lethargy)… • Outcome: Died, Euthanized, Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-068234
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Mixed
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Intravenous
  • Dose: 22 Milligram per kilogram
Reactions Reported:
Death Haematochezia Decreased appetite Regurgitation Tiredness (lethargy) Diarrhea Death by euthanasia
Outcomes: Died, Euthanized, Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

Store at room temperature.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.